Targets › TACR1
8 programs from 8 companies in 12 trials: 6 Phase 2, 4 Phase 3, 1 Phase 1, 1 Phase 4; Other, Metabolic and endocrine, Genitourinary; next expected readout Dec 2026.
Receptor for the tachykinin substance P, also able to bind and respond to tachynins neurokinin A/substance K and neurokinin B/neuromedin-K. The rank order of affinity of this receptor to tachykinins is: substance P > neurokinin A/substance K > neurokinin B/neuromedin-K. Substance P binding to its receptor triggers G protein-coupled receptor signaling via activation of phosphatidylinositol hydrolysis by phospholipase…. (UniProt, P25103)
Open in Phaseline: the race on TACR1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Shanghai 6th People's Hospital | Fosaprepitant Neurokinin 1 receptor antagonist | TACR1 | Phase 4 | Chemotherapy-induced Nausea and Vomiting | Dec 2026 |
| Vanda Pharmaceuticals | Tradipitant Neurokinin 1 receptor antagonist | TACR1 | Phase 3 | Idiopathic Gastroparesis; Nausea and Vomiting; Motion Sickness | Dec 2026 |
| Bayer | Elinzanetant (BAY3427080) Neurokinin 1 receptor antagonist; Neurokinin 3 receptor antagonist | TACR1, TACR3 | Phase 3 | Vasomotor Symptoms Caused by Adjuvant Endocrine Therapy in Women With, or at High Risk for Developing Hormone-receptor Positive Breast Cancer; Vasomotor Symptoms as a Sex Hormone-dependent Disorder in Women; Menopause-related Hot Flashes | Feb 2027 |
| IWK Health Centre | Aprepitant Neurokinin 1 receptor antagonist | TACR1 | Phase 2 | Spinal Fusion | Mar 2027 |
| Montefiore Medical Center | Fosaprepitant Neurokinin 1 receptor antagonist | TACR1 | Phase 2 | Nausea and Vomiting | Mar 2027 |
| University Hospital, Rouen | Aprepitant Neurokinin 1 receptor antagonist | TACR1 | Phase 2 | Apnea, Obstructive | Jun 2027 |
| Helsinn Healthcare | Fosnetupitant Neurokinin 1 receptor antagonist | TACR1 | Phase 2 | Nausea and Vomiting Chemotherapy-Induced | Oct 2027 |
| Tianjin Medical University Cancer Institute and Hospital | Fosrolapitant NK1 receptor antagonist | TACR1 | Phase 2 | Chemotherapy-Induced Nausea and Vomiting (CINV) | Jun 2028 |
Nausea and Vomiting (2) Nausea and Vomiting Chemotherapy-Induced (1) Idiopathic Gastroparesis (1) Motion Sickness (1) Vasomotor Symptoms Caused by Adjuvant Endocrine Therapy in Women With, or at High Risk for Developing Hormone-receptor Positive Breast Cancer (1) Vasomotor Symptoms as a Sex Hormone-dependent Disorder in Women (1) Menopause-related Hot Flashes (1) Apnea, Obstructive (1) Chemotherapy-Induced Nausea and Vomiting (CINV) (1) Spinal Fusion (1) Chemotherapy-induced Nausea and Vomiting (1)
small molecule (8)
Helsinn Healthcare (1) Vanda Pharmaceuticals (1) Bayer (1) University Hospital, Rouen (1) Tianjin Medical University Cancer Institute and Hospital (1) IWK Health Centre (1) Shanghai 6th People's Hospital (1) Montefiore Medical Center (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.